Articles

This white paper investigates best practices and tangible benefits associated with a risk-based quality management (RBQM) approach to clinical trial management.

Analysis of Risk-Based Quality Management Approach - White Paper

Life sciences transformations rarely fail because of what was in the plan. They fail because of what was not. Explore five trends that will determine their success in coming years.


Flip the Script

Gain actionable insights from Lash Group experts, leveraging 30+ years of experience launching new programs to help you ensure patient support success. 

Patient Support Launch Guide: Novel Therapies

Analysis of Risk-Based Quality Management Approach

Acoustic Ejection Mass Spectrometry:  The Era of High-Throughput Mass Spectrometry 

Industry experts cover how to develop digital patient solutions that address real unmet needs and secure adoption.


Digital patient solutions: the secret to delivering and securing adoption

In this case study, learn how to increase payer engagement, drive awareness, monitor competition, and leverage insights to enhance strategic plans and  launch success.

Gaining Payer Attention Through Digital Innovation

With bigger patient access and affordability barriers given the new normal of COVID-19, see why field services are more important than ever. Read now.

Solving access, reimbursement, and PAP awareness problems

This whitepaper discusses the importance of patient support programs and why a robust risk mitigation plan is critical to ensure that patients receive their therapy during crises.

Patient Support Programs: Considerations for Crisis Management and Risk Mitigation

In today’s fast-paced marketplace and complicated regulatory environment, operating in the life sciences industry can bring a variety of challenges. From raising capital or addressing pricing pressures to prioritizing development efforts or managing third-party risks, the landscape of Biopharma Finance is changing.

The Changing Landscape of Biopharma Finance 

With the future of face-to-face field sales uncertain, how can pharma ensure product messaging reaches the right healthcare audiences and, ultimately, patients?

Manufacturer’s Guide to Omnichannel Marketing

Don’t Just Capture Data, Collect it

Three Necessary Steps When Designing your New World Protocol Summary

Accelerate Launch Readiness: Strategies to Stay Ahead of the Curve

Compliance officers from the life sciences industry joined together recently to discuss how the COVID-19 pandemic has changed the ways we live and work, and how those changes have impacted the life sciences industry as a whole and will continue to do so in the future.

COVID-19 Action Plan for Ethics and Compliance Teams

Hospitals represent a critical access point for many therapeutics. Whether a therapeutic is indicated for use exclusively in a hospital or in both inpatient and outpatient settings, hospitals are key points of drug initiation or switching. To gain access to this channel, pharma companies must understand the needs and differences of hospital systems. 

Tips for Promoting Drug Update in Hospitals

MasterControl’s new e-book proves how the adoption of a data-driven and technology-supported approach to product life cycle management differentiates pharma leaders.


Connecting and Leveraging Quality-Driven Data

Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.


Managing the COVID-19 Drug Safety Response

Virtual elements in clinical trials require extra considerations 
All teams involved should maintain ongoing dialogue and collaboration for success
A discussion with industry leaders provides insight into such trials 
 


Virtual, Decentralized, Site-less Trials …What Does it All Mean

An overview of marketing during the COVID-19 crisis and how to utilize various tactical solutions to successfully reach your targeted healthcare professional audiences.



All Whitepapers